Investigational New Drugs

Aims & Scope

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research.

Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents.

The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist.

Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.7
2024	3.00

SJR (SCImago Journal Rank)

Year	Value
2024	1.074

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	100

Journal Rank

Year	Value
2024	4282

Journal Citation Indicator

Year	Value
2024	1298

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

  Citation: 732

  Authors: Muhammad S., Andrew J., Jasgit, Mitesh, Yoon-Koo, Jay, Susan, Andreas G., Sinil, David S.

• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

  Citation: 496

  Authors: Stephanie, Geoffrey R.

• Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

  Citation: 477

  Authors: Lawrence M., Shufen, Xi, Concepcion, Miriam, Maria Jose, Raquel, Rose T., Graham N., Robert Steven, Blake Lee, Jamie, Edward M., Philip, Damien, Emiko, Alfonso

• Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic

  Citation: 430

  Authors: Robert M.

• Matrix metalloproteinase inhibitors

  Citation: 362

  Authors: Slawomir M., Robert B., Michael J.

• A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

  Citation: 342

  Authors: Jonathan E., Richard M., Eliezer M., Harry A., Primo N., Andrea L., Nikhil, Robert A., Gregory W., Levi A., Toni, Fredrik, Damian A.

• Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

  Citation: 341

  Authors: Suzanne, Sjaak A., Paul, Dick, Matthijs, Erik, Enzo, Gianni, Jos H., Jan H. M.

• Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

  Citation: 339

  Authors: Kenneth J., Jean-Pascal, Dirk, Boris, Mikhail, Simon J., Susan, Shobha, Thomas A., Chris, Yusri, Fitzroy, Johann S.

• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  Citation: 334

  Authors: Susan M., Patrick, Timothy, Harry, David, Charles, Karen, H. Ian, Lisa, Jeffrey, Kenneth, Ken, Kathleen R., John, Janet, Michael D.

• 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development

  Citation: 326

  Authors: Jean L.

---